Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dietary supplement, ear drop ads referred to enforcement agencies

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division of the Council of Better Business Bureaus will refer ads for dietary supplement Lipodrene to the Federal Trade Commission and FDA because marketer Hi-Tech Pharmaceuticals failed to respond to a NAD inquiry, the watchdog group reports Oct. 8. NAD challenged a number of the ads' unsubstantiated health-related and weight-loss claims. Separately, the agency will refer advertising for Similasan Corporation USA's Earache Relief Ear Drops to "appropriate federal agencies" after the company refused to comply with certain recommendations in a NAD decision. The agency found the advertiser's clinical studies unreliable and ad claims unsubstantiated. NAD has recently been able to expand dietary supplement reviews in light of grants from the Council for Responsible Nutrition (1"The Tan Sheet" Sept. 25, 2006 p. 7)...

You may also be interested in...

CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring

CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts